ID   INP5E_HUMAN             Reviewed;         644 AA.
AC   Q9NRR6; Q15734; Q6PIV5;
DT   29-MAR-2004, integrated into UniProtKB/Swiss-Prot.
DT   04-NOV-2008, sequence version 2.
DT   15-MAR-2017, entry version 135.
DE   RecName: Full=72 kDa inositol polyphosphate 5-phosphatase;
DE            EC=3.1.3.36 {ECO:0000269|PubMed:10764818};
DE   AltName: Full=Phosphatidylinositol 4,5-bisphosphate 5-phosphatase;
DE   AltName: Full=Phosphatidylinositol polyphosphate 5-phosphatase type IV;
DE   Flags: Precursor;
GN   Name=INPP5E;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), FUNCTION, CATALYTIC
RP   ACTIVITY, ENZYME REGULATION, AND TISSUE SPECIFICITY.
RC   TISSUE=Fetal brain;
RX   PubMed=10764818; DOI=10.1074/jbc.M910119199;
RA   Kisseleva M.V., Wilson M.P., Majerus P.W.;
RT   "The isolation and characterization of a cDNA encoding phospholipid-
RT   specific inositol polyphosphate 5-phosphatase.";
RL   J. Biol. Chem. 275:20110-20116(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 469-644 (ISOFORM 1).
RA   Nussbaum R.L.;
RL   Submitted (JAN-1996) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-99, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,
RA   Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,
RA   Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [7]
RP   SUBCELLULAR LOCATION, AND INVOLVEMENT IN MORMS.
RX   PubMed=19668215; DOI=10.1038/ng.427;
RA   Jacoby M., Cox J.J., Gayral S., Hampshire D.J., Ayub M., Blockmans M.,
RA   Pernot E., Kisseleva M.V., Compere P., Schiffmann S.N., Gergely F.,
RA   Riley J.H., Perez-Morga D., Woods C.G., Schurmans S.;
RT   "INPP5E mutations cause primary cilium signaling defects, ciliary
RT   instability and ciliopathies in human and mouse.";
RL   Nat. Genet. 41:1027-1031(2009).
RN   [8]
RP   SUBCELLULAR LOCATION, VARIANTS JBTS1 CYS-378; GLN-435; TRP-512;
RP   TRP-515; HIS-563 AND GLU-580, AND CHARACTERIZATION OF VARIANTS JBTS1
RP   CYS-378; GLN-435; TRP-512; TRP-515; HIS-563 AND GLU-580.
RX   PubMed=19668216; DOI=10.1038/ng.423;
RA   Bielas S.L., Silhavy J.L., Brancati F., Kisseleva M.V., Al-Gazali L.,
RA   Sztriha L., Bayoumi R.A., Zaki M.S., Abdel-Aleem A., Rosti R.O.,
RA   Kayserili H., Swistun D., Scott L.C., Bertini E., Boltshauser E.,
RA   Fazzi E., Travaglini L., Field S.J., Gayral S., Jacoby M.,
RA   Schurmans S., Dallapiccola B., Majerus P.W., Valente E.M.,
RA   Gleeson J.G.;
RT   "Mutations in INPP5E, encoding inositol polyphosphate-5-phosphatase E,
RT   link phosphatidyl inositol signaling to the ciliopathies.";
RL   Nat. Genet. 41:1032-1036(2009).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-99, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [10]
RP   INTERACTION WITH PDE6D, SUBCELLULAR LOCATION, ISOPRENYLATION AT
RP   CYS-641, AND MUTAGENESIS OF CYS-641.
RX   PubMed=24166846; DOI=10.1002/humu.22470;
RA   Thomas S., Wright K.J., Le Corre S., Micalizzi A., Romani M.,
RA   Abhyankar A., Saada J., Perrault I., Amiel J., Litzler J., Filhol E.,
RA   Elkhartoufi N., Kwong M., Casanova J.L., Boddaert N., Baehr W.,
RA   Lyonnet S., Munnich A., Burglen L., Chassaing N., Encha-Ravazi F.,
RA   Vekemans M., Gleeson J.G., Valente E.M., Jackson P.K., Drummond I.A.,
RA   Saunier S., Attie-Bitach T.;
RT   "A homozygous PDE6D mutation in Joubert syndrome impairs targeting of
RT   farnesylated INPP5E protein to the primary cilium.";
RL   Hum. Mutat. 35:137-146(2014).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 275-623.
RG   Structural genomics consortium (SGC);
RT   "Crystal structure of human INPP5E.";
RL   Submitted (NOV-2010) to the PDB data bank.
RN   [12]
RP   VARIANTS JBTS1 ARG-286; MET-303; SER-345; ASN-426; GLN-435; ARG-474;
RP   ASP-534; HIS-563; CYS-585; GLN-621 AND ARG-641.
RX   PubMed=23386033; DOI=10.1038/ejhg.2012.305;
RG   International JSRD Study Group;
RA   Travaglini L., Brancati F., Silhavy J., Iannicelli M., Nickerson E.,
RA   Elkhartoufi N., Scott E., Spencer E., Gabriel S., Thomas S.,
RA   Ben-Zeev B., Bertini E., Boltshauser E., Chaouch M., Cilio M.R.,
RA   de Jong M.M., Kayserili H., Ogur G., Poretti A., Signorini S.,
RA   Uziel G., Zaki M.S., Johnson C., Attie-Bitach T., Gleeson J.G.,
RA   Valente E.M.;
RT   "Phenotypic spectrum and prevalence of INPP5E mutations in Joubert
RT   syndrome and related disorders.";
RL   Eur. J. Hum. Genet. 21:1074-1078(2013).
RN   [13]
RP   VARIANT JBTS1 GLN-621, AND INVOLVEMENT IN JBTS1.
RX   PubMed=23034536; DOI=10.1038/jhg.2012.117;
RA   Tsurusaki Y., Kobayashi Y., Hisano M., Ito S., Doi H., Nakashima M.,
RA   Saitsu H., Matsumoto N., Miyake N.;
RT   "The diagnostic utility of exome sequencing in Joubert syndrome and
RT   related disorders.";
RL   J. Hum. Genet. 58:113-115(2013).
CC   -!- FUNCTION: Converts phosphatidylinositol 3,4,5-trisphosphate
CC       (PtdIns 3,4,5-P3) to PtdIns-P2, and phosphatidylinositol 4,5-
CC       bisphosphate to phosphatidylinositol 4-phosphate. Specific for
CC       lipid substrates, inactive towards water soluble inositol
CC       phosphates. {ECO:0000269|PubMed:10764818}.
CC   -!- CATALYTIC ACTIVITY: 1-phosphatidyl-1D-myo-inositol 4,5-
CC       bisphosphate + H(2)O = 1-phosphatidyl-1D-myo-inositol 4-phosphate
CC       + phosphate. {ECO:0000269|PubMed:10764818}.
CC   -!- ENZYME REGULATION: Active in the presence of octyl-glucoside or
CC       Triton X-100, but completely inhibited by CTAB.
CC       {ECO:0000269|PubMed:10764818}.
CC   -!- SUBUNIT: Interacts (when prenylated) with PDE6D; this is important
CC       for normal location in cilia. {ECO:0000269|PubMed:24166846}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, cilium axoneme
CC       {ECO:0000269|PubMed:19668215, ECO:0000269|PubMed:19668216,
CC       ECO:0000269|PubMed:24166846}. Golgi apparatus, Golgi stack
CC       membrane {ECO:0000250|UniProtKB:Q9JII1}; Peripheral membrane
CC       protein {ECO:0000250|UniProtKB:Q9JII1}; Cytoplasmic side
CC       {ECO:0000250|UniProtKB:Q9JII1}. Cell membrane
CC       {ECO:0000250|UniProtKB:Q9WVR1}; Peripheral membrane protein
CC       {ECO:0000250|UniProtKB:Q9WVR1}; Cytoplasmic side
CC       {ECO:0000250|UniProtKB:Q9WVR1}. Cell projection, ruffle
CC       {ECO:0000250|UniProtKB:Q9WVR1}. Cytoplasm
CC       {ECO:0000250|UniProtKB:Q9WVR1}. Note=Peripheral membrane protein
CC       associated with Golgi stacks. {ECO:0000250|UniProtKB:Q9JII1}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9NRR6-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9NRR6-2; Sequence=VSP_009799;
CC   -!- TISSUE SPECIFICITY: Detected in brain, heart, pancreas, testis and
CC       spleen. {ECO:0000269|PubMed:10764818}.
CC   -!- DISEASE: Joubert syndrome 1 (JBTS1) [MIM:213300]: A disorder
CC       presenting with cerebellar ataxia, oculomotor apraxia, hypotonia,
CC       neonatal breathing abnormalities and psychomotor delay.
CC       Neuroradiologically, it is characterized by cerebellar vermian
CC       hypoplasia/aplasia, thickened and reoriented superior cerebellar
CC       peduncles, and an abnormally large interpeduncular fossa, giving
CC       the appearance of a molar tooth on transaxial slices (molar tooth
CC       sign). Additional variable features include retinal dystrophy and
CC       renal disease. {ECO:0000269|PubMed:19668216,
CC       ECO:0000269|PubMed:23034536, ECO:0000269|PubMed:23386033}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Mental retardation, truncal obesity, retinal dystrophy,
CC       and micropenis (MORMS) [MIM:610156]: An autosomal recessive
CC       disorder characterized by moderate mental retardation, truncal
CC       obesity, congenital non-progressive retinal dystrophy, and
CC       micropenis in males. The phenotype is similar to Bardet-Biedl
CC       syndrome and Cohen syndrome Distinguishing features are the age of
CC       onset, the non-progressive nature of the visual impairment, lack
CC       of dysmorphic facies, skin or gingival infection, microcephaly,
CC       mottled retina, polydactyly, and testicular anomalies.
CC       {ECO:0000269|PubMed:19668215}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the inositol 1,4,5-trisphosphate 5-
CC       phosphatase type IV family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB03215.1; Type=Miscellaneous discrepancy; Note=Several sequencing problems.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF187891; AAF81404.1; -; mRNA.
DR   EMBL; AL592301; CAI13947.1; -; Genomic_DNA.
DR   EMBL; CH471090; EAW88234.1; -; Genomic_DNA.
DR   EMBL; BC028032; AAH28032.1; -; mRNA.
DR   EMBL; U45974; AAB03215.1; ALT_SEQ; mRNA.
DR   CCDS; CCDS7000.1; -. [Q9NRR6-1]
DR   RefSeq; NP_001305431.1; NM_001318502.1.
DR   RefSeq; NP_063945.2; NM_019892.5. [Q9NRR6-1]
DR   UniGene; Hs.120998; -.
DR   PDB; 2XSW; X-ray; 1.90 A; A/B=275-623.
DR   PDBsum; 2XSW; -.
DR   ProteinModelPortal; Q9NRR6; -.
DR   SMR; Q9NRR6; -.
DR   IntAct; Q9NRR6; 3.
DR   STRING; 9606.ENSP00000360777; -.
DR   SwissLipids; SLP:000001180; -.
DR   DEPOD; Q9NRR6; -.
DR   iPTMnet; Q9NRR6; -.
DR   PhosphoSitePlus; Q9NRR6; -.
DR   BioMuta; INPP5E; -.
DR   DMDM; 212276439; -.
DR   MaxQB; Q9NRR6; -.
DR   PaxDb; Q9NRR6; -.
DR   PeptideAtlas; Q9NRR6; -.
DR   PRIDE; Q9NRR6; -.
DR   Ensembl; ENST00000371712; ENSP00000360777; ENSG00000148384. [Q9NRR6-1]
DR   GeneID; 56623; -.
DR   KEGG; hsa:56623; -.
DR   UCSC; uc004cho.4; human. [Q9NRR6-1]
DR   CTD; 56623; -.
DR   DisGeNET; 56623; -.
DR   GeneCards; INPP5E; -.
DR   GeneReviews; INPP5E; -.
DR   H-InvDB; HIX0125641; -.
DR   HGNC; HGNC:21474; INPP5E.
DR   HPA; HPA065758; -.
DR   MalaCards; INPP5E; -.
DR   MIM; 213300; phenotype.
DR   MIM; 610156; phenotype.
DR   MIM; 613037; gene.
DR   neXtProt; NX_Q9NRR6; -.
DR   OpenTargets; ENSG00000148384; -.
DR   Orphanet; 475; Joubert syndrome.
DR   Orphanet; 1454; Joubert syndrome with hepatic defect.
DR   Orphanet; 220493; Joubert syndrome with ocular defect.
DR   Orphanet; 75858; MORM syndrome.
DR   PharmGKB; PA164741785; -.
DR   eggNOG; KOG0565; Eukaryota.
DR   eggNOG; COG5411; LUCA.
DR   GeneTree; ENSGT00760000119075; -.
DR   HOGENOM; HOG000231541; -.
DR   HOVERGEN; HBG052132; -.
DR   InParanoid; Q9NRR6; -.
DR   KO; K20278; -.
DR   OMA; SCSPPCL; -.
DR   OrthoDB; EOG091G05DT; -.
DR   PhylomeDB; Q9NRR6; -.
DR   TreeFam; TF323475; -.
DR   BioCyc; MetaCyc:HS09270-MONOMER; -.
DR   BRENDA; 3.1.3.36; 2681.
DR   Reactome; R-HSA-1660514; Synthesis of PIPs at the Golgi membrane.
DR   Reactome; R-HSA-5624958; ARL13B-mediated ciliary trafficking of INPP5E.
DR   ChiTaRS; INPP5E; human.
DR   GenomeRNAi; 56623; -.
DR   PRO; PR:Q9NRR6; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; ENSG00000148384; -.
DR   CleanEx; HS_INPP5E; -.
DR   Genevisible; Q9NRR6; HS.
DR   GO; GO:0005930; C:axoneme; IDA:UniProtKB.
DR   GO; GO:0005929; C:cilium; TAS:Reactome.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0032580; C:Golgi cisterna membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0001726; C:ruffle; IEA:UniProtKB-SubCell.
DR   GO; GO:0004445; F:inositol-polyphosphate 5-phosphatase activity; TAS:UniProtKB.
DR   GO; GO:0004439; F:phosphatidylinositol-4,5-bisphosphate 5-phosphatase activity; TAS:Reactome.
DR   GO; GO:0046855; P:inositol phosphate dephosphorylation; IEA:Ensembl.
DR   GO; GO:0006661; P:phosphatidylinositol biosynthetic process; TAS:Reactome.
DR   GO; GO:0046856; P:phosphatidylinositol dephosphorylation; IEA:Ensembl.
DR   Gene3D; 3.60.10.10; -; 1.
DR   InterPro; IPR005135; Endo/exonuclease/phosphatase.
DR   InterPro; IPR000300; IPPc.
DR   Pfam; PF03372; Exo_endo_phos; 1.
DR   SMART; SM00128; IPPc; 1.
DR   SUPFAM; SSF56219; SSF56219; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane; Cell projection;
KW   Ciliopathy; Cilium; Complete proteome; Cytoplasm; Cytoskeleton;
KW   Disease mutation; Golgi apparatus; Hydrolase; Joubert syndrome;
KW   Lipid metabolism; Lipoprotein; Membrane; Mental retardation;
KW   Methylation; Obesity; Phosphoprotein; Polymorphism; Prenylation;
KW   Reference proteome; Repeat.
FT   CHAIN         1    641       72 kDa inositol polyphosphate 5-
FT                                phosphatase.
FT                                {ECO:0000305|PubMed:24166846}.
FT                                /FTId=PRO_0000209747.
FT   PROPEP      642    644       Removed in mature form.
FT                                {ECO:0000305|PubMed:24166846}.
FT                                /FTId=PRO_0000431688.
FT   REPEAT       10     13       1.
FT   REPEAT       15     18       2.
FT   REPEAT       28     31       3.
FT   REPEAT       39     42       4.
FT   REPEAT       55     58       5.
FT   REPEAT       69     71       6.
FT   REPEAT       72     74       7.
FT   REPEAT       75     78       8.
FT   REPEAT      121    124       9.
FT   REPEAT      169    172       10.
FT   REPEAT      183    185       11.
FT   REPEAT      190    193       12.
FT   REPEAT      236    239       13.
FT   REGION       10    242       13 X 4 AA repeats of P-X-X-P.
FT   COMPBIAS     92     97       Poly-Arg.
FT   MOD_RES      99     99       Phosphoserine.
FT                                {ECO:0000244|PubMed:17525332,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     241    241       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9WVR1}.
FT   MOD_RES     256    256       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9JII1}.
FT   MOD_RES     641    641       Cysteine methyl ester.
FT                                {ECO:0000305|PubMed:24166846}.
FT   LIPID       641    641       S-farnesyl cysteine.
FT                                {ECO:0000305|PubMed:24166846}.
FT   VAR_SEQ     346    379       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:10764818}.
FT                                /FTId=VSP_009799.
FT   VARIANT     201    201       I -> M (in dbSNP:rs36064831).
FT                                /FTId=VAR_047078.
FT   VARIANT     286    286       G -> R (in JBTS1; dbSNP:rs757936530).
FT                                {ECO:0000269|PubMed:23386033}.
FT                                /FTId=VAR_077247.
FT   VARIANT     303    303       V -> M (in JBTS1; dbSNP:rs746212325).
FT                                {ECO:0000269|PubMed:23386033}.
FT                                /FTId=VAR_077248.
FT   VARIANT     345    345       R -> S (in JBTS1).
FT                                {ECO:0000269|PubMed:23386033}.
FT                                /FTId=VAR_077249.
FT   VARIANT     378    378       R -> C (in JBTS1; slightly reduced
FT                                activity; dbSNP:rs121918130).
FT                                {ECO:0000269|PubMed:19668216}.
FT                                /FTId=VAR_063012.
FT   VARIANT     426    426       T -> N (in JBTS1).
FT                                {ECO:0000269|PubMed:23386033}.
FT                                /FTId=VAR_077250.
FT   VARIANT     435    435       R -> Q (in JBTS1; severe reduction of
FT                                activity; dbSNP:rs121918129).
FT                                {ECO:0000269|PubMed:19668216,
FT                                ECO:0000269|PubMed:23386033}.
FT                                /FTId=VAR_063013.
FT   VARIANT     474    474       W -> R (in JBTS1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:23386033}.
FT                                /FTId=VAR_077251.
FT   VARIANT     512    512       R -> W (in JBTS1; associated with W-515;
FT                                severe reduction of activity;
FT                                dbSNP:rs374152018).
FT                                {ECO:0000269|PubMed:19668216}.
FT                                /FTId=VAR_063014.
FT   VARIANT     515    515       R -> W (in JBTS1; associated with W-512;
FT                                severe reduction of activity;
FT                                dbSNP:rs13297509).
FT                                {ECO:0000269|PubMed:19668216}.
FT                                /FTId=VAR_063015.
FT   VARIANT     534    534       Y -> D (in JBTS1).
FT                                {ECO:0000269|PubMed:23386033}.
FT                                /FTId=VAR_077252.
FT   VARIANT     563    563       R -> H (in JBTS1; slightly reduced
FT                                activity; dbSNP:rs121918128).
FT                                {ECO:0000269|PubMed:19668216,
FT                                ECO:0000269|PubMed:23386033}.
FT                                /FTId=VAR_063016.
FT   VARIANT     580    580       K -> E (in JBTS1; severe reduction of
FT                                activity). {ECO:0000269|PubMed:19668216}.
FT                                /FTId=VAR_063017.
FT   VARIANT     585    585       R -> C (in JBTS1; dbSNP:rs763992407).
FT                                {ECO:0000269|PubMed:23386033}.
FT                                /FTId=VAR_077253.
FT   VARIANT     621    621       R -> Q (in JBTS1).
FT                                {ECO:0000269|PubMed:23034536,
FT                                ECO:0000269|PubMed:23386033}.
FT                                /FTId=VAR_076892.
FT   VARIANT     641    641       C -> R (in JBTS1).
FT                                {ECO:0000269|PubMed:23386033}.
FT                                /FTId=VAR_077254.
FT   MUTAGEN     641    641       C->A: Abolishes farnesylation-dependent
FT                                interaction with PDE6D.
FT                                {ECO:0000269|PubMed:24166846}.
FT   CONFLICT    345    345       R -> T (in Ref. 1; AAF81404).
FT                                {ECO:0000305}.
FT   HELIX       287    293       {ECO:0000244|PDB:2XSW}.
FT   STRAND      298    307       {ECO:0000244|PDB:2XSW}.
FT   HELIX       319    322       {ECO:0000244|PDB:2XSW}.
FT   STRAND      332    340       {ECO:0000244|PDB:2XSW}.
FT   HELIX       345    356       {ECO:0000244|PDB:2XSW}.
FT   STRAND      360    368       {ECO:0000244|PDB:2XSW}.
FT   STRAND      371    378       {ECO:0000244|PDB:2XSW}.
FT   HELIX       379    384       {ECO:0000244|PDB:2XSW}.
FT   STRAND      389    399       {ECO:0000244|PDB:2XSW}.
FT   STRAND      402    413       {ECO:0000244|PDB:2XSW}.
FT   STRAND      416    424       {ECO:0000244|PDB:2XSW}.
FT   HELIX       432    445       {ECO:0000244|PDB:2XSW}.
FT   STRAND      450    452       {ECO:0000244|PDB:2XSW}.
FT   HELIX       457    459       {ECO:0000244|PDB:2XSW}.
FT   HELIX       465    467       {ECO:0000244|PDB:2XSW}.
FT   STRAND      468    477       {ECO:0000244|PDB:2XSW}.
FT   STRAND      482    484       {ECO:0000244|PDB:2XSW}.
FT   HELIX       486    493       {ECO:0000244|PDB:2XSW}.
FT   HELIX       501    505       {ECO:0000244|PDB:2XSW}.
FT   HELIX       509    515       {ECO:0000244|PDB:2XSW}.
FT   STRAND      518    520       {ECO:0000244|PDB:2XSW}.
FT   STRAND      540    543       {ECO:0000244|PDB:2XSW}.
FT   STRAND      556    564       {ECO:0000244|PDB:2XSW}.
FT   STRAND      567    575       {ECO:0000244|PDB:2XSW}.
FT   STRAND      581    584       {ECO:0000244|PDB:2XSW}.
FT   STRAND      587    594       {ECO:0000244|PDB:2XSW}.
FT   HELIX       611    623       {ECO:0000244|PDB:2XSW}.
SQ   SEQUENCE   644 AA;  70205 MW;  5B6CFB75CD0ADC9A CRC64;
     MPSKAENLRP SEPAPQPPEG RTLQGQLPGA PPAQRAGSPP DAPGSESPAL ACSTPATPSG
     EDPPARAAPI APRPPARPRL ERALSLDDKG WRRRRFRGSQ EDLEARNGTS PSRGSVQSEG
     PGAPAHSCSP PCLSTSLQEI PKSRGVLSSE RGSPSSGGNP LSGVASSSPN LPHRDAAVAG
     SSPRLPSLLP PRPPPALSLD IASDSLRTAN KVDSDLADYK LRAQPLLVRA HSSLGPGRPR
     SPLACDDCSL RSAKSSFSLL APIRSKDVRS RSYLEGSLLA SGALLGADEL ARYFPDRNVA
     LFVATWNMQG QKELPPSLDE FLLPAEADYA QDLYVIGVQE GCSDRREWET RLQETLGPHY
     VLLSSAAHGV LYMSLFIRRD LIWFCSEVEC STVTTRIVSQ IKTKGALGIS FTFFGTSFLF
     ITSHFTSGDG KVAERLLDYT RTVQALVLPR NVPDTNPYRS SAADVTTRFD EVFWFGDFNF
     RLSGGRTVVD ALLCQGLVVD VPALLQHDQL IREMRKGSIF KGFQEPDIHF LPSYKFDIGK
     DTYDSTSKQR TPSYTDRVLY RSRHKGDICP VSYSSCPGIK TSDHRPVYGL FRVKVRPGRD
     NIPLAAGKFD RELYLLGIKR RISKEIQRQQ ALQSQNSSTI CSVS
//
